Diagnostic significance of serum osteopontin level for pancreatic cancer: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 8, 2014, Pages 580-586

  Li, Jian Jun ^a   Li, Hong Yu ^b   Gu, Fei ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; TUMOR PROTEIN;

ARTICLE; ASIAN; CANCER PATIENT; CAUCASIAN; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ETHNICITY; HUMAN; META ANALYSIS; PANCREAS CANCER; PROTEIN BLOOD LEVEL; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL (TOPIC); FEMALE; MALE; PANCREATIC NEOPLASMS;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; NEOPLASM PROTEINS; OSTEOPONTIN; PANCREATIC NEOPLASMS;

EID: 84905642943     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2014.0102     Document Type: Article

References (39)

1. Anderson LN, Cotterchio M, Gallinger S (2009) Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada. Cancer Causes Control 20:825-834.
2. Brand RE, Nolen BM, Zeh HJ, et al. (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17:805-816.
3. Chang IC, Chiang TI, Yeh KT, et al. (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21:1401-1409.
4. Chen R, Crispin DA, Pan S, et al. (2010) Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas 39:981-988.
5. Chen ZG, Li QJ (2011) Association the detection of Opn, Cea, Ca125, and Ca19-9 and the diagnosis of pancreatic cancer. J Henan Med Col Staff Workers 23:181-182.
6. Cho H, Hong SW, Oh YJ, et al. (2008) Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol 134:909-917.
7. Cho HJ, Kim HS (2009) Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep 11:206-213.
8. Ferrone CR, Brennan MF, Gonen M, et al. (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12:701-706.
9. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605-1617.
10. Inoue M, Shinohara ML (2011) Intracellular osteopontin (iOPN) and immunity. Immunol Res 49:160-172.
11. Iodice S, Gandini S, Maisonneuve P, et al. (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393:535-545.
12. Kolb A, Kleeff J, Guweidhi A, et al. (2005) Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther 4:740-746.
13. Koopmann J, Rosenzweig CN, Zhang Z, et al. (2006) Serum markers in patients with resectable pancreatic adenocarcino-ma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12:442-446.
14. Landi S (2009) Genetic predisposition and environmental risk factors to pancreatic cancer: a review of the literature. Mutat Res 681:299-307.
15. Maisonneuve P, Lowenfels AB (2010) Epidemiology of pancreatic cancer: an update. Dig Dis 28:645-656.
16. Mi Z, Bhattacharya SD, Kim VM, et al. (2011) Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 32:477-487.
17. Mi Z, Guo H, Russell MB, et al. (2009) RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther 17:153-161.
18. Murugaiyan G, Mittal A, Weiner HL (2010) Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-gamma limits IL-17-mediated autoimmune inflammation. Proc Natl Acad Sci USA 107:11495-11500.
19. Narisawa S, Yadav MC, Millan JL (2013) In vivo overexpression of tissue-nonspecific alkaline phosphatase increases skeletal mineralization and affects the phosphorylation status of os-teopontin. J Bone Miner Res 28:1587-1598.
20. Peters JL, Sutton AJ, Jones DR, et al. (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295:676-680.
21. Poruk KE, Firpo MA, Scaife CL, et al. (2013) Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 42:193-197.
22. Ramaiah SK, Rittling S (2008) Pathophysiological role of os-teopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 103:4-13.
23. Rud AK, Boye K, Oijordsbakken M, et al. (2013) Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer 13:540.
24. Scatena M, Liaw L, Giachelli CM (2007) Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 27:2302-2309.
25. Shang S, Plymoth A, Ge S, et al. (2012) Identification of os-teopontin as a novel marker for early hepatocellular carcinoma. Hepatology 55:483-490.
26. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
27. Sreekanthreddy P, Srinivasan H, Kumar DM, et al. (2010) Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 19:1409-1422.
28. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603-605.
29. Sullivan J, Blair L, Alnajar A, et al. (2009) Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 146:232-240.
30. Takahashi F, Kumasaka T, Nagaoka T, et al. (2009) Osteopontin expression in pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Pathol Int 59:752-756.
31. Takenaka M, Hanagiri T, Shinohara S, et al. (2013) Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer. Clin Lung Cancer 14:288-294.
32. Wang KX, Denhardt DT (2008) Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 19:333-345.
33. Yang SQ, Li XM, He F, et al. (2010) Clinical significance of detection of serum osteopontin in patient with pancreatic cancer. Labor Med Clin 7:1281-1282.
34. Yang YC, Zhao YP, Liao Q, et al. (2007) Evaluation of os-teopontin as serum tumor marker for pancreatic cancer. Chin J Practical Surg 27:821-823.
35. Zhang X, Eirin A, Lerman A, et al. (2013) Osteopontin: an emerging therapeutic target in uraemic vascular disease. Cardiovasc Res 98:332-333.
36. Zhang ZM, Guo JM, Wang XB, et al. (2010) Measurement of serum osteopontin in patients with pancreatic cancer and its clinical significance. Zhejiang Med J 32:644-645.
37. Zhivkova-Galunska M, Adwan H, Eyol E, et al. (2010) Os-teopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines. Cancer Biol Ther 10:54-64.
38. Zhu RQ (2011) Association the detection of Opn, Cea, Ca125, and Ca19-9 and the diagnosis of pancreatic cancer. Chin Manipulation Rehabil Med 2:49.
39. Zintzaras E, Ioannidis JP (2005) HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 21:3672-3673.